Loading...
ALK-Abelló A/S
AKBLF•PNK
Healthcare
Biotechnology
$30.44
$0.00(0.00%)
ALK-Abelló A/S (AKBLF) Financial Performance & Income Statement Overview
Review ALK-Abelló A/S’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
14.78%
↑ 14.78%
Operating Income Growth
63.81%
↑ 63.81%
Net Income Growth
67.70%
↑ 67.70%
Operating Cash Flow Growth
81.86%
↑ 81.86%
Operating Margin
21.76%
↑ 21.76%
Gross Margin
64.45%
↑ 64.45%
Net Profit Margin
16.42%
↑ 16.42%
ROE
17.80%
↑ 17.80%
ROIC
18.86%
↑ 18.86%
ALK-Abelló A/S (AKBLF) Income Statement & Financial Overview
Review ALK-Abelló A/S's (AKBLF) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $1.50B | $1.31B | $1.37B | $1.35B |
| Cost of Revenue | $545.00M | $471.00M | $507.00M | $462.00M |
| Gross Profit | $954.00M | $842.00M | $867.00M | $889.00M |
| Gross Profit Ratio | $0.64 | $0.64 | $0.63 | $0.66 |
| R&D Expenses | $167.00M | $109.00M | $125.00M | $130.00M |
| SG&A Expenses | $582.00M | $427.00M | $480.00M | $444.00M |
| Operating Expenses | $749.00M | $536.00M | $603.00M | $573.00M |
| Total Costs & Expenses | $1.29B | $1.007B | $1.11B | $1.03B |
| Interest Income | $0.00 | $0.00 | $5.00M | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $76.00M | $63.00M | $67.00M | $66.00M |
| EBITDA | $312.00M | $369.00M | $331.00M | $382.00M |
| EBITDA Ratio | $0.21 | $0.28 | $0.24 | $0.28 |
| Operating Income | $205.00M | $306.00M | $264.00M | $316.00M |
| Operating Income Ratio | $0.14 | $0.23 | $0.19 | $0.23 |
| Other Income/Expenses (Net) | -$7.00M | -$25.00M | $5.00M | -$7.00M |
| Income Before Tax | $198.00M | $281.00M | $269.00M | $309.00M |
| Income Before Tax Ratio | $0.13 | $0.21 | $0.20 | $0.23 |
| Income Tax Expense | $28.00M | $69.00M | $68.00M | $77.00M |
| Net Income | $170.00M | $212.00M | $201.00M | $232.00M |
| Net Income Ratio | $0.11 | $0.16 | $0.15 | $0.17 |
| EPS | $0.77 | $1.00 | $0.91 | $1.10 |
| Diluted EPS | $0.77 | $1.00 | $0.91 | $1.10 |
| Weighted Avg Shares Outstanding | $221.40M | $212.00M | $221.33M | $210.91M |
| Weighted Avg Shares Outstanding (Diluted) | $222.14M | $212.00M | $221.33M | $210.91M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan